Centiva Capital, LP Aeglea Bio Therapeutics, Inc. Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
A detailed history of Centiva Capital, LP transactions in Aeglea Bio Therapeutics, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 14,200 shares of AGLE stock, worth $392,772. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,200Holding current value
$392,772% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding AGLE
# of Institutions
1Shares Held
241KCall Options Held
0Put Options Held
0About Aeglea BioTherapeutics, Inc.
- Ticker AGLE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,172,500
- Market Cap $1.69B
- Description
- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...